Tags

Type your tag names separated by a space and hit enter

Metoclopramide-associated tardive dyskinesia in hemodialysis patients with diabetes mellitus. Two case reports.
Gen Hosp Psychiatry 1992; 14(6):416-9GH

Abstract

Metoclopramide, a drug used almost exclusively for medical indications, is a dopamine (D-2) receptor blocker and has been reported to cause extrapyramidal side effects. We present two case reports of hemodialysis patients who were treated with metoclopramide for diabetic gastroparesis. Within 12 months of beginning treatment, both patients developed persistent tardive dyskinesia. These cases highlight the fact that some patients who benefit from metoclopramide may also have a relatively high risk of developing persistent tardive dyskinesia. The consultation-liaison psychiatrist can play an important role in the education of the medical staff regarding metoclopramide-induced tardive dyskinesia.

Links

  • Publisher Full Text

    • Authors+Show Affiliations

    Sewell DD
    University of California, San Diego.
    Yoshinobu BH
    No affiliation info available
    Caligiuri MP
    No affiliation info available
    Jeste DV
    No affiliation info available

    MeSH

    AdultDiabetes Mellitus, Type 1Diabetic NephropathiesDyskinesia, Drug-InducedHumansMaleMetoclopramideMiddle AgedProspective StudiesPsychiatryReferral and ConsultationRenal DialysisStomach Diseases

    Pub Type(s)

    Case Reports
    Journal Article
    Research Support, U.S. Gov't, Non-P.H.S.
    Research Support, U.S. Gov't, P.H.S.

    Language

    eng

    PubMed ID

    1473712

    Citation

    Sewell, D D., et al. "Metoclopramide-associated Tardive Dyskinesia in Hemodialysis Patients With Diabetes Mellitus. Two Case Reports." General Hospital Psychiatry, vol. 14, no. 6, 1992, pp. 416-9.
    Sewell DD, Yoshinobu BH, Caligiuri MP, et al. Metoclopramide-associated tardive dyskinesia in hemodialysis patients with diabetes mellitus. Two case reports. Gen Hosp Psychiatry. 1992;14(6):416-9.
    Sewell, D. D., Yoshinobu, B. H., Caligiuri, M. P., & Jeste, D. V. (1992). Metoclopramide-associated tardive dyskinesia in hemodialysis patients with diabetes mellitus. Two case reports. General Hospital Psychiatry, 14(6), pp. 416-9.
    Sewell DD, et al. Metoclopramide-associated Tardive Dyskinesia in Hemodialysis Patients With Diabetes Mellitus. Two Case Reports. Gen Hosp Psychiatry. 1992;14(6):416-9. PubMed PMID: 1473712.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Metoclopramide-associated tardive dyskinesia in hemodialysis patients with diabetes mellitus. Two case reports. AU - Sewell,D D, AU - Yoshinobu,B H, AU - Caligiuri,M P, AU - Jeste,D V, PY - 1992/11/1/pubmed PY - 1992/11/1/medline PY - 1992/11/1/entrez SP - 416 EP - 9 JF - General hospital psychiatry JO - Gen Hosp Psychiatry VL - 14 IS - 6 N2 - Metoclopramide, a drug used almost exclusively for medical indications, is a dopamine (D-2) receptor blocker and has been reported to cause extrapyramidal side effects. We present two case reports of hemodialysis patients who were treated with metoclopramide for diabetic gastroparesis. Within 12 months of beginning treatment, both patients developed persistent tardive dyskinesia. These cases highlight the fact that some patients who benefit from metoclopramide may also have a relatively high risk of developing persistent tardive dyskinesia. The consultation-liaison psychiatrist can play an important role in the education of the medical staff regarding metoclopramide-induced tardive dyskinesia. SN - 0163-8343 UR - https://www.unboundmedicine.com/medline/citation/1473712/Metoclopramide_associated_tardive_dyskinesia_in_hemodialysis_patients_with_diabetes_mellitus__Two_case_reports_ L2 - https://linkinghub.elsevier.com/retrieve/pii/0163-8343(92)90009-Y DB - PRIME DP - Unbound Medicine ER -